Review



dna microarray  (CustomArray Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    CustomArray Inc dna microarray
    Dna Microarray, supplied by CustomArray Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+oligonucleotide+microarray/dna+microarray/10__1007_slash_bf03259646-57-10-0
    Average 90 stars, based on 1 article reviews
    dna microarray - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Microarray:

    Article Title: Summary of Recent Deal Activity
    Article Snippet: Companies Type of Deal Details Allergan, R&D agreement ExonHit Therapeutics has extended its strategic alliance with Allergan, based on the positive ExonHit results achieved to date.. This will enable both companies to continue their successful Therapeutics collaboration for the discovery and development of new therapeutics in the fields of neurodegenerative diseases, pain and ophthalmology.. In relation to this new agreement, ExonHit has received an additional payment of $US2 million from Allergan.



    Similar Products

    customised oligonucleotide microarray  (Agilent technologies)
    90
    Agilent technologies customised oligonucleotide microarray
    Customised Oligonucleotide Microarray, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+oligonucleotide+microarray/pm25195018-60-10-12
    Average 90 stars, based on 1 article reviews
    customised oligonucleotide microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    customised 11 kb oligonucleotide-microarray  (Agilent technologies)
    90
    Agilent technologies customised 11 kb oligonucleotide-microarray
    Relative expression levels of GATA-4 and friend-of-GATA ( FOG )-2 according to <t>microarray</t> analyses. ( A – D ) GATA-4 and ( E – H ) FOG-2 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =32 for GATA-4 ; n =33 for FOG-2 ). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Boxes: median expression values (horizontal line) and twenty-fifth and seventy-fifth percentiles; whiskers: distances from the end of the box to the largest and smallest observed values that are <1.5 box lengths from either end of the box; open circles: outlying values; asterisks: extreme values. ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.
    Customised 11 Kb Oligonucleotide Microarray, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+oligonucleotide+microarray/pmc02768442-36-29-31
    Average 90 stars, based on 1 article reviews
    customised 11 kb oligonucleotide-microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Relative expression levels of GATA-4 and friend-of-GATA ( FOG )-2 according to microarray analyses. ( A – D ) GATA-4 and ( E – H ) FOG-2 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =32 for GATA-4 ; n =33 for FOG-2 ). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Boxes: median expression values (horizontal line) and twenty-fifth and seventy-fifth percentiles; whiskers: distances from the end of the box to the largest and smallest observed values that are <1.5 box lengths from either end of the box; open circles: outlying values; asterisks: extreme values. ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Journal: British Journal of Cancer

    Article Title: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes

    doi: 10.1038/sj.bjc.6605276

    Figure Lengend Snippet: Relative expression levels of GATA-4 and friend-of-GATA ( FOG )-2 according to microarray analyses. ( A – D ) GATA-4 and ( E – H ) FOG-2 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =32 for GATA-4 ; n =33 for FOG-2 ). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Boxes: median expression values (horizontal line) and twenty-fifth and seventy-fifth percentiles; whiskers: distances from the end of the box to the largest and smallest observed values that are <1.5 box lengths from either end of the box; open circles: outlying values; asterisks: extreme values. ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Article Snippet: In brief, 1 μ g of linearly amplified Cy3- and Cy5-labelled cRNA was hybridised together with 1 μ g of reverse colour Cy-labelled reference cRNA to a customised 11 kb oligonucleotide-microarray (Agilent Technologies, Waldbronn, Germany).

    Techniques: Expressing, Microarray, Amplification, MANN-WHITNEY

    Relative expression levels of GATA-2 and -3 according to microarray analyses. ( A – D ) GATA-2 and ( E – H ) GATA-3 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =33). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Box plots represent data as in . * P <0.05; ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Journal: British Journal of Cancer

    Article Title: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes

    doi: 10.1038/sj.bjc.6605276

    Figure Lengend Snippet: Relative expression levels of GATA-2 and -3 according to microarray analyses. ( A – D ) GATA-2 and ( E – H ) GATA-3 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =33). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Box plots represent data as in . * P <0.05; ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Article Snippet: In brief, 1 μ g of linearly amplified Cy3- and Cy5-labelled cRNA was hybridised together with 1 μ g of reverse colour Cy-labelled reference cRNA to a customised 11 kb oligonucleotide-microarray (Agilent Technologies, Waldbronn, Germany).

    Techniques: Expressing, Microarray, Amplification, MANN-WHITNEY